The following is a summary of “Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival,” published in ...

The patient may also experience an abnormally high or abnormally low blood pressure in nephrotic syndrome (DiSalvo et al., 2002; Khan & Falk, 2001). Amyloid protein can limit the ability of the ...

[Ash 2020;5b] Amyloidoses which can affect the heart include: Amyloid light-chain (AL) amyloidosis (also known as primary amyloidosis), caused by aggregation of monoclonal kappa or lambda light ...

Tove Jensen-Munroe’s AL amyloidosis diagnosis “derailed” her life. The avid cyclist, walker, and swimmer was studying a ...

The company also reported accelerated enrollment in the ongoing NEXICART-2 study, which is evaluating the safety and efficacy of NXC-201 in AL amyloidosis patients. NXC-201 is the only CAR-T ...

The deal gives the Anglo-Swedish drugmaker complete control of Caelum's late-stage medicine for light chain (AL) amyloidosis, a potentially fatal disease that causes the rogue protein amyloid to ...

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for ...

Lower skeletal muscle mass was associated with an increased risk for short- and long-term mortality in patients with cardiac amyloidosis (CA). This association was particularly strong with ...